35.172.217.174
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Oculoplastics-AAO
Oculoplastics-ASOPRS

Anti-TNF alpha agents may be effective treatment for thyroid eye disease

Posted on May 3, 2021
Anti-TNF alpha agents may be effective treatment for thyroid eye disease

Anti-TNF alpha agents appear to be effective in the treatment of patients with active thyroid eye disease (TED) who cannot take corticosteroids, according to a poster presented at ARVO2021.

Researchers used data from 8 patients with TED who received anti-TNF alpha agents after showing resistance to or not being able to take steroid therapy. Anti-TNF alpha agents included infliximab (n = 3), etanercept (n = 3), and adalimumab (n = 2). All patients were followed for at least 9 months.

CAS score and proptosis value decreased from baseline to after treatments from 5.5 (SD= 1.69) to 0.5 (SD= 0.75) and 24.12 mm (SD= 2.23) to 22.12 (SD=1.88), respectively.

Patients treated with adalimumab had a resolution of diplopia and a decrease in proptosis compared to those treated with the other agents.

There were no complications associated with the use of anti-TNF alpha agents.

Reference
Pakdel F, et al. Efficacy of anti-TNF-alpha agents in active thyroid eye disease. Presented at: ARVO 2021

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-